--- schema_version: "secwatch.filing_event.v1" accession: "0001628280-23-022677" form_type: "8-K" ticker: "NAGE" cik: "0001386570" company_name: "Niagen Bioscience, Inc." filed_at: "2023-06-20T23:59:59+00:00" generated_at: "2026-06-13T21:02:56.922392+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.55 calibrated_materiality_score: 0.55 confidence: "high" source: SEC EDGAR --- # ChromaDex shareholders approve equity plan increase, reject preferred stock authorization ## Summary - Stockholders approved amendment to 2017 Equity Incentive Plan, increasing shares available by 3.65M. - Proposal to authorize 5M shares of preferred stock failed (36.2M for, 8.7M against, 181k abstain). - All eight director nominees elected with over 36M votes for each (largest withheld 8.5M for Steven Rubin). - Advisory approval of executive compensation passed with 43.6M for, 1.44M against. - Ratification of Marcum LLP as auditor for FY2023 approved (53.1M for, 3.0M against). ## SEC filing metadata - accession: 0001628280-23-022677 - form_type: 8-K - ticker: NAGE - cik: 0001386570 - company_name: Niagen Bioscience, Inc. - filed_at: 2023-06-20T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.55 - calibrated_materiality_score: 0.55 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/0001628280-23-022677-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/cdxc-20230615.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001628280-23-022677 - JSON: https://secwatch.observer/filing/0001628280-23-022677.json - Plain text: https://secwatch.observer/filing/0001628280-23-022677.txt ## Key facts - Shareholder Votes Niagen Bioscience, Inc. shareholders rejected Approval of amendment to the Company’s certificate of incorporation to authorize the issuance of up to 5 million shares of preferred stock. - Proposal: charter amendment - Outcome: failed source text: Proposal 5 — Approval of amendment to the Company’s certificate of incorporation to authorize the issuance of up to 5 million shares of preferred stock. For Against Abstain Broker Non-Votes 36,184,125 8,688,172 181,120 11,176,909 Based on the votes set forth above, the proposed amendment to the Company’s certificate of incorporation was not approved by the Company’s stockholders. evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/0001628280-23-022677-index.htm - Shareholder Votes Niagen Bioscience, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers. - Proposal: say on pay - Outcome: passed source text: Proposal 3 — Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers. For Against Abstain Broker Non-Votes 43,580,102 1,443,544 29,771 11,176,909 evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/0001628280-23-022677-index.htm - Shareholder Votes Niagen Bioscience, Inc. shareholders approved Approval of amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares available for issuance by 3.65 million shares of common stock. - Proposal: equity plan - Outcome: passed source text: Proposal 4 — Approval of amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares available for issuance by 3.65 million shares of common stock. For Against Abstain Broker Non-Votes 39,844,772 5,156,391 52,254 11,176,909 evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/0001628280-23-022677-index.htm - Shareholder Votes Niagen Bioscience, Inc. shareholders approved Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-12-31 source text: Proposal 2 — Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain Broker Non-Votes 53,073,220 2,985,840 171,266 * * No broker non-votes arose in connection with Proposal 2. evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/0001628280-23-022677-index.htm - Shareholder Votes Niagen Bioscience, Inc. shareholders approved Election of directors. - Proposal: director election - Outcome: passed source text: Proposal 1 — Election of directors. The following directors were elected to serve until the Company’s 2024 Annual Meeting of Stockholders and until his or her successor is elected, or, if sooner, until such director’s death, resignation or removal. Director Elected For Withheld Broker Non-Votes Frank L. Jaksch, Jr. 43,991,870 1,061,547 11,176,909 Robert Fried 43,766,801 1,286,616 11,176,909 Steven Rubin 36,576,757 8,476,660 11,176,909 Wendy Yu 44,381,475 671,942 11,176,909 Gary Ng 44,320,738 732,679 11,176,909 Kristin Patrick 44,152,241 901,176 11,176,909 Ann Cohen 44,137,364 916,053 11,176,909 Hamed Shahbazi 43,164,410 1,889,007 11,176,909 evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/0001628280-23-022677-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.